Welcome to our dedicated page for Polyrizon news (Ticker: PLRZ), a resource for investors and traders seeking the latest updates and insights on Polyrizon stock.
Polyrizon Ltd. (Nasdaq: PLRZ) generates news as a development-stage biotechnology company focused on intranasal hydrogels and barrier-forming nasal sprays. Company announcements highlight progress across its Capture and Contain™ (C&C) and Trap & Target™ (T&T) platforms, including updates on allergy, viral exposure reduction, and intranasal drug delivery programs.
Readers following Polyrizon news can expect coverage of preclinical study results, regulatory interactions, and product branding milestones. Recent press releases describe positive in-vitro data for PL-14 Allergy Blocker, including allergen-blocking performance compared with a standard comparator, and the completion of a branding process that will see PL-14 marketed as NASARIX™. Other updates focus on PL-16 Viral Blocker, a non-pharmacological intranasal hydrogel spray designed to form a temporary physical barrier on the nasal mucosa, with reported preclinical evidence of protection against certain respiratory viruses.
Polyrizon also reports on the advancement of its intranasal naloxone hydrogel within the Trap & Target™ platform. News items detail mucoadhesion and permeation studies comparing the formulation to a marketed intranasal naloxone product, as well as broader commentary on the potential role of enhanced mucosal residence time in emergency opioid overdose reversal.
In addition to R&D and regulatory milestones, Polyrizon’s news flow includes strategic and corporate developments. The company has disclosed plans to explore revenue-generating investment opportunities in sectors such as defense, aviation, artificial intelligence, and real assets, alongside continued focus on its core medical pipeline. Investors and observers can use this news stream to monitor scientific progress, FDA-related steps such as pre-submission meetings and Pre-Request for Designation filings, capital structure actions like reverse share splits, and broader strategic decisions that may influence the PLRZ stock story over time.
Polyrizon (Nasdaq: PLRZ) filed a divisional European patent application on April 27, 2026, for its Trap & Target (T&T) intranasal drug delivery platform. The filing targets protection for prolonged nasal residence, improved bioavailability, controlled release, drip prevention, biodegradable polymers, and broad drug compatibility.
The application complements a recent U.S. patent filing covering both T&T and Capture & Contain (C&C) platform technologies.
Polyrizon (NASDAQ: PLRZ) closed a registered direct offering and concurrent private placement on April 8, 2026, raising approximately $3.5 million in aggregate gross proceeds.
The transactions sold 388,888 Units or Pre-Funded Units at $9.00 per Unit (or $8.99999 per Pre-Funded Unit), included Pre-Funded Warrants and Common Warrants exercisable at $9.00, and result in 2,083,939 Ordinary Shares outstanding assuming all pre-funded warrants are exercised.
Polyrizon (NASDAQ: PLRZ) announced a registered direct offering and concurrent private placement expected to raise approximately $3.5 million. The transactions include 388,888 Units or Pre-Funded Units at $9.00 each and warrants exercisable at $9.00 per share.
Closing is expected on or about April 8, 2026, subject to customary conditions; Aegis Capital is acting as exclusive placement agent.
Polyrizon (Nasdaq: PLRZ) closed 2025 with approximately $17.5 million in cash, a debt-free balance sheet and multiple preclinical and regulatory milestones. Key actions include an FDA Pre-Submission for PL-14 (NASARIX™), a Pre-RFD for PL-16, GMP manufacturing of clinical material, and a Q2 2026 CRO study start.
The company reported positive preclinical data for an intranasal naloxone hydrogel, successful intranasal delivery for PL-14, manufacturing upscaling progress, and non-binding initiatives to explore investments in private aviation and eVTOL drone technologies.
Polyrizon (Nasdaq: PLRZ) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on March 25, 2026.
The report is available on the SEC website and Polyrizon’s investor relations site; shareholders may request a free copy from Investor Relations at IR@polyrizon-biotech.com.
Polyrizon (Nasdaq: PLRZ) signed a non-binding MOU to acquire up to a 20% stake in Colugo Systems, an Israeli developer of advanced eVTOL drones, for up to US $6,000,000 payable in cash or Polyrizon shares.
The MOU requires a definitive agreement, corporate approvals, resolution of rights of first refusal or co-sale, and is expected to close promptly (within 7 days after conditions). The MOU expires on September 30, 2026 if not closed earlier.
Polyrizon (Nasdaq: PLRZ) signed an agreement with a leading global preclinical CRO to run ISO 10993‑compliant, GLP biocompatibility studies as part of its clinical development program.
The studies are expected to begin in Q2 2026, follow recent GMP production of clinical material, an FDA pre‑submission meeting, and positive preclinical allergen‑blocking data, supporting a potential start of clinical trials later in 2026.
Polyrizon (Nasdaq: PLRZ) announced successful GMP manufacturing of a clinical trial material (CTM) batch with Eurofins CDMO AmatsiAquitaine S.A.S on March 10, 2026. The GMP batch follows two development batches showing batch-to-batch consistency and stability and supports a planned U.S. clinical study later in 2026.
This milestone advances Polyrizon's intranasal platform toward clinical testing and regulatory submissions for its lead product candidate.
Polyrizon (Nasdaq: PLRZ) announced a comparative pre-clinical study showing its naloxone nasal formulation achieved 94.6% (±4.0%) deposition in the nasal vestibule and upper turbinate versus 79.6% (±3.0%) for a commercial reference product.
The study used a validated silicone nasal cast and quantitative imaging; Polyrizon reported lower lower-turbinate deposition (5.4% vs. 20.4%), which may reduce posterior runoff and improve dosing consistency for intranasal systemic delivery.
Polyrizon (Nasdaq: PLRZ) unveiled NASARIX™ on Feb 17, 2026, branding its lead intranasal allergy product and completing U.S. and European trademark screening. NASARIX™ uses Capture and Contain™ hydrogel to form a drug‑free nasal barrier; preclinical data show superior allergen blocking versus common comparators. A human factors/usability study began Jan 22, 2026, and clinical trials are expected to start in Q3 2026, with the company positioning NASARIX™ as a medical device to pursue a streamlined regulatory path.